Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.

Haemophilia : the Official Journal of the World Federation of Hemophilia
Hande KizilocakGuy Young

Abstract

Emicizumab is a recombinant, humanized bispecific monoclonal antibody that mimics the function of factor VIII (FVIII) which results in a significant reduction in the annualized bleeding rate in patients with haemophilia A (HA), however, the degree with which emicizumab corrects the coagulation defect remains unclear. The objective of this study was to predict the approximate FVIII level in severe haemophilia A patients with inhibitors on emicizumab using global haemostasis assays. Patients with moderate and mild HA in the non-bleeding state and healthy controls had FVIII levels and thrombin generation assessed. Linear regression was utilized to model the FVIII levels as a function of the thrombin generation assay parameters and to make a calibration curve of FVIII levels versus peak thrombin and endogenous thrombin potential. Patients with severe haemophilia A with inhibitors on emicizumab had thrombin generation performed in the same manner and their peak thrombin and endogenous thrombin potential results were placed on the calibration curve to calculate their FVIII Equivalency of Emicizumab by Thrombin Generation (F8EmT). All patients with severe HA with inhibitors on emicizumab had F8EmT >10%, suggesting they had been conver...Continue Reading

References

Jul 12, 2017·The New England Journal of Medicine·Johannes OldenburgMidori Shima
Jun 12, 2018·Journal of Thrombosis and Haemostasis : JTH·R HartmannF Scheiflinger
Aug 30, 2018·The New England Journal of Medicine·Johnny MahlanguRebecca Kruse-Jarres
Mar 20, 2019·Journal of Thrombosis and Haemostasis : JTH·Nina C LeksaJoe Salas
May 6, 2020·Blood·Stephen FerrièreCécile V Denis
May 13, 2020·Blood Advances·Peter J Lenting

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

© 2021 Meta ULC. All rights reserved